We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, today announced the introduction of its...
NEW YORK, Nov. 17 /PRNewswire/ -- Standard & Poor's will make the following changes to the S&P 100, S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices: -- Wyeth (NYSE:WYE) will replace...
Invitrogen Corporation (NASDAQ:IVGN) today announced progress against its integration plans regarding its pending merger with Applied Biosystems. The company announced that...
DALLAS, Oct. 30 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today. Investors can view all of the daily trading notes for free by visiting:...
Invitrogen Corporation (Nasdaq:IVGN) today announced results for its third quarter ended September 30,?2008. Revenues for the third quarter were $362?million, an increase...
Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, today announced the introduction of a new...
As a part of its continued commitment to environmental sustainability, Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research...
Invitrogen Corporation (NASDAQ:IVGN) today announced that the company has completed a significant milestone in the integration planning for the Applied Biosystems combination...
Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, today congratulates the three winners of the...
Families of Spinal Muscular Atrophy (FSMA, www.curesma.org), Invitrogen Corporation (NASDAQ:IVGN)(www.invitrogen.com), and deCODE chemistry & biostructures...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions